Researchers assess the psychosocial impact of allogeneic hematopoietic stem cell transplantation, particularly how preparing patients can assist in guiding health care providers in offering better care.
In managing allogeneic hematopoietic stem cell transplantation (allo-HSCT), clinical outcomes, as well as psychosocial aspects can prove beneficial in improving care delivery. Researchers of a study published in European Journal of Cancer Care sought to better determine the psychosocial impact of the procedure.
Reviewing qualitative studies addressing this impact, researchers have identified a wide range of stressors and various coping mechanisms associated with allo-HSCT that they say shed a light on the social meaning of stressors following the procedure and coping strategies used to re-adjust.
The data from 20 interviews with allo-HSCT survivors revealed 72 stressors across 7 categories:
In addition to a broad array of stressors the interviews also revealed coping mechanisms used by patients included direct efforts to manage problems, such as using a wig or hat for hair loss and avoiding unsafe situations; adaptive attitudes, such as accepting the state of side effects; and seeking and relying on social support.
“The findings of this study have clinical implications for the design and implementation of effective interventions for all-HSCT survivors,” conclude researchers. “Which can improve the quality of care delivered to this group and enhance post-treatment quality of life and adjustment.”
Reference
Kusaka K, Unoguchi H, Nakahara R, et al. Stress and coping strategies among allogeneic haematopoietic stem cell transplantation survivors: a qualitative study. Eur J Cancer Care. Published online September 5, 2020. doi:10.1111/ecc.13307
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Muscle-Directed Therapy Apitegromab Meets Primary End Point in Phase 3 SAPPHIRE Trial of SMA
October 17th 2024Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety profile consistent with long-term data, as Scholar Rock prepares for US and EU regulatory submissions in Q1 2025.
Read More